Colour blindness – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:51:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Colour blindness – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of rAAV.hCNGA3 for Adults and Minors with CNGA3-Linked Achromatopsia https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-raav-hcnga3-for-adults-and-minors-with-cnga3-linked-achromatopsia/ Wed, 29 Apr 2026 14:27:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-raav-hcnga3-for-adults-and-minors-with-cnga3-linked-achromatopsia/ This clinical trial is focused on studying the safety and effectiveness of a new treatment for CNGA3-linked achromatopsia, a genetic eye condition that affects color vision and visual clarity. The treatment being tested is called rAAV.hCNGA3, which is a solution for injection. It contains a special type of virus, known as an adeno-associated viral vector, that carries a human gene called CNGA3. This gene is delivered to the eye to help improve vision by targeting the specific genetic cause of the condition.

The purpose of the study is to evaluate how safe and effective this treatment is when injected into both eyes of patients, including both adults and children. Participants in the study will receive a single injection of the treatment under the retina, which is the light-sensitive layer at the back of the eye. The study is designed to compare the results of those who receive the treatment immediately with those who are placed on a waitlist, ensuring a fair assessment of the treatment’s impact.

Throughout the study, various tests will be conducted to monitor changes in vision, such as contrast sensitivity and visual acuity, which measures how well one can see details at different distances. Additionally, participants will be asked about their experiences and any changes they notice in their vision. The study aims to provide valuable information on whether this gene therapy can be a safe and effective option for improving vision in people with CNGA3-linked achromatopsia.

]]>